Johnson & Johnson (NYSE:JNJ) Position Raised by Kampmann Melissa S.

Kampmann Melissa S. raised its stake in Johnson & Johnson (NYSE:JNJ) by 1.9% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 24,036 shares of the company’s stock after buying an additional 445 shares during the quarter. Johnson & Johnson makes up about 3.2% of Kampmann Melissa S.’s investment portfolio, making the stock its 12th largest holding. Kampmann Melissa S.’s holdings in Johnson & Johnson were worth $3,767,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in Johnson & Johnson during the 4th quarter valued at about $4,071,642,000. International Assets Investment Management LLC grew its stake in Johnson & Johnson by 7,875.8% during the 4th quarter. International Assets Investment Management LLC now owns 2,090,384 shares of the company’s stock valued at $327,647,000 after acquiring an additional 2,064,175 shares in the last quarter. Janney Montgomery Scott LLC purchased a new position in Johnson & Johnson during the 4th quarter valued at about $193,050,000. abrdn plc grew its stake in Johnson & Johnson by 104.1% during the 4th quarter. abrdn plc now owns 2,014,743 shares of the company’s stock valued at $315,791,000 after acquiring an additional 1,027,441 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Johnson & Johnson by 10.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 10,169,190 shares of the company’s stock valued at $1,593,908,000 after acquiring an additional 975,485 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

JNJ has been the subject of several research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Monday, May 6th. StockNews.com downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Monday, June 10th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a research report on Tuesday, June 4th. Morgan Stanley dropped their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. Finally, Bank of America lowered their price objective on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Eight analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $174.07.

Johnson & Johnson Trading Up 0.1 %

NYSE:JNJ traded up $0.09 during mid-day trading on Friday, hitting $145.54. The company had a trading volume of 4,075,342 shares, compared to its average volume of 7,121,075. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The business’s fifty day moving average is $148.38 and its two-hundred day moving average is $154.67. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The firm has a market cap of $350.27 billion, a P/E ratio of 9.07, a P/E/G ratio of 2.42 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The firm had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. During the same quarter in the prior year, the firm posted $2.68 earnings per share. The company’s quarterly revenue was up 2.3% on a year-over-year basis. As a group, research analysts expect that Johnson & Johnson will post 10.63 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st were issued a $1.24 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.41%. The ex-dividend date of this dividend was Monday, May 20th. Johnson & Johnson’s dividend payout ratio is 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.